China Shineway Pharmaceutical Group Limited (C1S) — Capital Reinvestment Ratio
China Shineway Pharmaceutical Group Limited (C1S) has a Capital Reinvestment Ratio of 0.15x as of June 2023, meaning it reinvests 0% of its operating cash flow (€160.69 Million) in capital expenditures (€24.57 Million). Check C1S tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
China Shineway Pharmaceutical Group Limited Capital Reinvestment Ratio (2013–2025)
This chart tracks China Shineway Pharmaceutical Group Limited's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see C1S operating cash flow.
Annual Capital Reinvestment Ratio for China Shineway Pharmaceutical Group Limited (2013–2025)
Year-by-year Capital Reinvestment Ratio for China Shineway Pharmaceutical Group Limited from 2013 to 2025. See China Shineway Pharmaceutical Group Limi (C1S) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | €1.17 Billion | €197.91 Million | ▲ +16.1% |
| 2024 | 0.15x | €963.13 Million | €140.11 Million | ▼ -6.0% |
| 2023 | 0.15x | €932.63 Million | €144.32 Million | ▲ +32.6% |
| 2022 | 0.12x | €1.11 Billion | €129.46 Million | ▼ -12.4% |
| 2021 | 0.13x | €703.15 Million | €93.63 Million | ▲ +28.8% |
| 2020 | 0.10x | €638.57 Million | €66.03 Million | ▼ -57.0% |
| 2019 | 0.24x | €368.00 Million | €88.40 Million | ▲ +0.5% |
| 2018 | 0.24x | €532.59 Million | €127.34 Million | ▲ +27.8% |
| 2017 | 0.19x | €490.65 Million | €91.83 Million | ▲ +28.5% |
| 2016 | 0.15x | €733.53 Million | €106.79 Million | ▲ +1.7% |
| 2015 | 0.14x | €744.71 Million | €106.56 Million | ▲ +6.2% |
| 2014 | 0.13x | €773.16 Million | €104.18 Million | ▼ -73.3% |
| 2013 | 0.50x | €519.89 Million | €261.89 Million | — |